Actively Recruiting
Soluble B7-H3 as a Biomarker for Osteosarcoma
Led by Peking University People's Hospital · Updated on 2024-05-14
200
Participants Needed
1
Research Sites
82 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Increasing data has indicated an association between increased soluble B7-H3 (sB7-H3) levels and unfavorable prognosis in patients with malignancies. However, the level of sB7-H3 and its clinical significance in osteosarcoma are not well known. In this present study, we investigated whether sB7-H3 levels in serum could be as a biomarker for osteosarcoma treatment.
CONDITIONS
Official Title
Soluble B7-H3 as a Biomarker for Osteosarcoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- High-grade osteosarcoma confirmed by pathology
- No prior systemic treatment before the first blood draw
- ECOG performance status 0 or 1 and able to tolerate standard PKUPH-OS-02 neoadjuvant chemotherapy
- Complete radiographs available for clinical evaluation
You will not qualify if you...
- Unable to tolerate blood draws
- Incomplete medical records in the PKUPH system
- Unable to tolerate PKUPH-OS-02 neoadjuvant chemotherapy
- Other conditions deemed unsuitable by investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University People's Hospital
Beijing, Beijing Municipality, China, 100044
Actively Recruiting
Research Team
L
Lu Xie, M.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here